Verastem Oncology will present additional analyses from the Phase 2 RAMP 201 trial evaluating avutometinib plus defactinib in recurrent low-grade serous ovarian cancer at SGO 2025, building on their FDA Priority Review submission.
The FDA has granted Fast Track designation to SIGX1094, a potential targeted therapy for diffuse gastric cancer, to expedite its development and review.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.